GLP-1 vs Phentermine: Semaglutide, Tirzepatide, and How They Compare to an Older Stimulant

What Are GLP-1 Receptor Agonists and How Do They Differ From Phentermine?

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone that slows gastric emptying, suppresses glucagon, and acts on hypothalamic appetite centers to reduce caloric intake. Phentermine works by triggering norepinephrine release in the central nervous system, which blunts hunger through a stimulant pathway that shares a pharmacological family with amphetamines.

The distinction matters clinically. GLP-1 agents address multiple metabolic pathways simultaneously: they improve insulin sensitivity, lower fasting and postprandial glucose, and appear to reduce systemic inflammation. Phentermine does none of those things. Its action is narrower, faster in onset, and time-limited by both regulatory approval (short-term use only, generally defined as up to 12 weeks) and by tachyphylaxis, meaning appetite-suppressing effects tend to fade as the body adapts to the elevated norepinephrine signal.

Semaglutide (brand names Ozempic for type 2 diabetes, Wegovy for obesity) and tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) are the two GLP-1 agents with the strongest published weight-loss evidence. Tirzepatide adds a glucose-dependent insulinotropic polypeptide (GIP) agonist component, making it a dual agonist with a distinct receptor profile from semaglutide. Both are administered as once-weekly subcutaneous injections, escalated over 16-20 weeks to their maintenance doses. [1][2]

Semaglutide vs Tirzepatide: Which Produces More Weight Loss?

Tirzepatide consistently produces greater mean weight loss in controlled trials, though both agents far outperform phentermine on published data. In SURMOUNT-1 (N=2,539 to 72 weeks), tirzepatide 15 mg achieved a mean body-weight reduction of 20.9% vs. 3.1% for placebo. [3] In STEP-1 (N=1,961 to 68 weeks), semaglutide 2.4 mg achieved 14.9% vs. 2.4% for placebo (P<0.001). [1]

A direct head-to-head trial comparing the two molecules has not yet been published as a full randomized controlled trial, though the SURPASS-6 data in insulin-using type 2 diabetes patients showed tirzepatide's superiority on HbA1c and weight over semaglutide 1 mg. That comparison used the diabetes dose of semaglutide (1 mg), not the obesity dose (2.4 mg), so it does not directly answer which is better for weight loss at approved obesity-indication doses.

Long-term data also favor both agents strongly over phentermine. STEP-5 followed patients on semaglutide 2.4 mg for 104 weeks and found sustained mean weight loss of 15.2%, with 77.1% of participants maintaining at least 5% weight reduction throughout the entire two-year period. [4] SURMOUNT-4 demonstrated that tirzepatide patients who stopped active drug after 36 weeks regained approximately 14 percentage points of weight loss within 52 weeks, confirming that the mechanism requires ongoing therapy rather than a finite course. [5] Phentermine has no published 104-week efficacy data because regulatory guidance does not support its use beyond 12 weeks.

Clinical decision framework: GLP-1 dose titration and expected milestones

| Timepoint | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Phentermine | |-----------|---------------------|----------------------|-------------| | Week 4 | 0.25 mg/week | 2.5 mg/week | 15-37.5 mg/day (full dose from start) | | Week 16 | 1.0 mg/week | 5-10 mg/week | Reassess; typically discontinue | | Week 20 | 2.4 mg/week (maintenance) | 10-15 mg/week (maintenance) | Not approved beyond ~12 weeks | | Expected weight loss at maintenance | 10-15% mean at 1 year | 15-22% mean at 1 year | 3-5% over short course | | Cardiovascular outcome data | Yes (SELECT) | Phase 3 CV trial ongoing | No long-term CV outcomes data |

Wegovy vs Zepbound: Same Goal, Different FDA Labels

Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in June 2021, indicated for adults with a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity. [6] Zepbound (tirzepatide) received a parallel obesity indication in November 2023 with the same BMI thresholds. [7]

Both labels require use alongside a reduced-calorie diet and increased physical activity. Neither is approved as monotherapy without lifestyle modification. The Wegovy label also carries a boxed warning about thyroid C-cell tumors observed in rodent studies, a warning also present on Zepbound, though neither drug has shown human thyroid cancer causation in post-marketing surveillance to date. Phentermine carries a different set of contraindications: it is explicitly prohibited in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, and a history of drug abuse, restrictions that exclude a substantial portion of the typical obesity patient population. [6][7]

The American Association of Clinical Endocrinology (AACE) obesity clinical practice guidelines state that "anti-obesity medications should be used in conjunction with lifestyle therapy to increase total weight loss and help maintain weight loss." [8] That guidance predates the GLP-1 era for obesity but was reinforced by the 2024 AACE position statement endorsing GLP-1 agents as first-line pharmacotherapy when BMI criteria are met.

Ozempic vs Wegovy: Same Molecule, Different Doses and Indications

Ozempic and Wegovy both contain semaglutide, but the similarity ends there for clinical purposes. Ozempic is approved for type 2 diabetes management and cardiovascular risk reduction in adults with established cardiovascular disease; its maintenance dose is 0.5 mg, 1 mg, or 2 mg weekly. Wegovy is approved for chronic weight management at a fixed maintenance dose of 2.4 mg weekly. [6]

Using Ozempic off-label for weight loss means a patient receives at most 2 mg weekly, which is below the 2.4 mg dose proven in STEP-1, STEP-3, and STEP-5. STEP-3 (N=611) added intensive behavioral therapy to semaglutide 2.4 mg and found a mean weight loss of 16.0% at 68 weeks vs. 5.7% with behavioral therapy plus placebo. [9] That trial used 2.4 mg, not a sub-therapeutic 2 mg Ozempic dose. The difference between 2 mg and 2.4 mg may appear small numerically, but the dose-response curve for semaglutide is steep enough that the gap in weight outcomes is clinically meaningful.

From a supply and insurance perspective, Ozempic shortages have driven some prescribers toward Wegovy and vice versa. Patients should be aware that these are different FDA approvals with different indication codes, affecting insurance coverage.

Mounjaro vs Zepbound: Identical Molecule, Separate Approvals

Mounjaro and Zepbound contain the same active ingredient, tirzepatide, at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly). Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. This is a direct parallel to the Ozempic/Wegovy situation. [7]

SURMOUNT-2 (N=938 to 72 weeks) evaluated tirzepatide in adults with type 2 diabetes and obesity, finding mean weight loss of 13.9% with 15 mg vs. 3.3% with placebo (P<0.001), confirming meaningful weight reduction even in the more metabolically resistant type 2 diabetes population. [10] SURMOUNT-3 (N=579) tested tirzepatide after a 12-week intensive lifestyle run-in period, producing an additional 18.4% weight loss on top of the 2.4% already achieved through lifestyle alone. [11]

Prescribing Mounjaro off-label for obesity is common in practice, particularly when Zepbound faces supply constraints, but the indication mismatch complicates insurance reimbursement. Some commercial payers require a Zepbound prescription specifically for obesity billing, while others accept tirzepatide under either brand.

GLP-1 Cardiovascular Benefits vs Phentermine's Cardiovascular Risks

This comparison is perhaps the most clinically decisive factor when choosing between the drug classes. Phentermine is a sympathomimetic that raises heart rate and blood pressure. Short-term use at therapeutic doses typically increases resting heart rate by 5-10 beats per minute and systolic blood pressure by a similar magnitude. Long-term cardiovascular outcome data simply do not exist because phentermine is not approved for long-term use.

GLP-1 agents have now accumulated strong cardiovascular outcomes trial data. The SELECT trial (N=17,604, mean follow-up 39.8 months) enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 20% compared to placebo (6.5% vs. 8.0%, hazard ratio 0.80 to 95% CI 0.72-0.90, P<0.001). [12] This was the first trial to show a GLP-1 agent reducing MACE in a non-diabetic population.

Dr. A. Michael Lincoff, principal investigator of SELECT, stated: "These results indicate that the cardiovascular benefits of semaglutide extend beyond glucose-lowering and weight reduction, suggesting direct cardioprotective mechanisms." [12] A comparable cardiovascular outcomes trial for tirzepatide (SURPASS-CVOT) is ongoing, with results anticipated in 2026.

The clinical implication is straightforward: in a patient with existing cardiovascular disease and obesity, prescribing phentermine would be contraindicated by its own FDA label while semaglutide carries a demonstrated cardiovascular benefit.

Side Effect Profiles: What Patients Actually Experience

GLP-1 agents and phentermine have non-overlapping side effect profiles. Knowing which profile a patient can tolerate often determines which drug they stay on long enough to benefit from.

GLP-1 gastrointestinal effects. Nausea is the most common adverse event with semaglutide and tirzepatide, affecting roughly 40-44% of patients at some point during titration. Vomiting, diarrhea, and constipation each affect 10-30% of patients. Most GI events are mild to moderate and peak during dose escalation, typically resolving within 4-8 weeks of reaching a stable dose. In STEP-1 to 7.0% of semaglutide patients discontinued due to adverse events vs. 3.1% in the placebo group. [1]

Phentermine stimulant effects. Dry mouth, insomnia, palpitations, increased blood pressure, restlessness, and headache are the dominant complaints. Tolerance to appetite suppression develops over weeks, which is one reason the FDA restricts prescribing to short-term courses. Phentermine is a Schedule IV controlled substance in the United States, requiring DEA-compliant prescribing.

Gallbladder disease. Rapid weight loss from any cause increases gallstone risk. GLP-1 agents appear to slow gallbladder motility directly, and cholelithiasis rates in STEP-1 were 1.6% with semaglutide vs. 0.7% with placebo. [1] Patients with a history of gallbladder disease require closer monitoring on either agent.

Injection site reactions. Both semaglutide and tirzepatide are weekly subcutaneous injections. Injection-site erythema and nodules occur in roughly 5-7% of patients but rarely cause discontinuation. Phentermine requires no injections.

Who Should Consider Phentermine Instead of a GLP-1 Agent?

Phentermine still has a clinical role, primarily for patients who cannot access or afford GLP-1 agents and need short-term appetite suppression while building sustainable dietary habits. A few specific scenarios favor phentermine or phentermine-topiramate extended-release (the combination product Qsymia):

Patients with BMI <30 who do not qualify for GLP-1 reimbursement may obtain phentermine at low cost through primary care. Patients who strongly prefer oral medication over weekly injections may find phentermine-topiramate ER more acceptable. For patients requiring rapid pre-surgical weight loss over 8-12 weeks, phentermine's faster onset (pharmacologically active within hours, vs. GLP-1 agents requiring 16-20 weeks of titration) may serve a narrow bridging role.

Phentermine-topiramate ER (Qsymia) produces greater weight loss than phentermine alone, with CONQUER trial data showing approximately 8.1-9.8% mean weight loss at 56 weeks depending on dose, still below GLP-1 outcomes but meaningfully better than phentermine monotherapy.

The AACE guidelines note that combination oral agents such as phentermine-topiramate ER are appropriate second-line or third-line options when GLP-1 injectables are contraindicated, not tolerated, or cost-prohibitive. [8]

Cost and Access: The Practical Reality

List prices for Wegovy and Zepbound run approximately $1,300-$1,400 per month in the United States as of early 2025. Manufacturer savings cards (Novo Nordisk's savings offer for Wegovy, Eli Lilly's savings card for Zepbound) can reduce out-of-pocket costs to as low as $0-$25 per month for commercially insured patients who qualify. Medicare currently does not cover anti-obesity medications under Part D, though the Treat and Reduce Obesity Act, if passed, would change this.

Generic phentermine costs $20-$60 per month at most pharmacies. No prior authorization is required for most prescribers. The access disparity between the drug classes is real and ethically significant: the patients with the greatest metabolic burden are often those with the least insurance flexibility.

Compounded semaglutide and tirzepatide from 503B outsourcing facilities occupied a legal grey zone during the FDA shortage period. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in early 2025, meaning compounded versions of both molecules should no longer be legally available from 503A compounding pharmacies. Patients currently receiving compounded GLP-1s should consult their prescriber about transitioning to an FDA-approved product.

STEP and SURMOUNT Trials at a Glance: Numbers That Matter

Phentermine has no comparable trial infrastructure. The contrast in evidence quality is stark.

STEP-1 (N=1,961): Semaglutide 2.4 mg, 68 weeks. Mean weight loss 14.9% vs. 2.4% placebo (P<0.001). 86.4% of semaglutide patients achieved 5% weight loss vs. 31.5% placebo. [1]

STEP-2 (N=1,210): Semaglutide in adults with type 2 diabetes and obesity. Mean weight loss 9.6% at 68 weeks vs. 3.4% placebo. [13]

STEP-8 (N=338): Semaglutide 2.4 mg vs. liraglutide 3.0 mg, 68 weeks. Semaglutide produced 15.8% mean weight loss vs. 6.4% for liraglutide (P<0.001), settling the intra-class comparison decisively in semaglutide's favor. [14]

SURMOUNT-1 (N=2,539): Tirzepatide 5/10/15 mg, 72 weeks. Mean weight loss 15.0%, 19.5%, and 20.9% respectively vs. 3.1% placebo. At 15 mg, 57.8% of patients achieved 20% or greater weight loss. [3]

SURMOUNT-3 (N=579): Tirzepatide after intensive lifestyle run-in. Mean additional weight loss 18.4% on drug vs. 2.5% on placebo after the run-in period. [11]

Phentermine's weight loss data, when pooled across older short-term trials, show a mean of approximately 3.6 kg (roughly 3-5% of body weight) over 12 weeks compared to placebo, based on a 2019 systematic review in Obesity Reviews (N=12 trials). No 52-week or 104-week phentermine monotherapy data exist in the modern evidence base.

STEP-2 and Type 2 Diabetes: Semaglutide's Glycemic Dimension

Patients with type 2 diabetes considering GLP-1 therapy gain a dual benefit: weight loss and glycemic control. STEP-2 (N=1,210) found semaglutide 2.4 mg reduced HbA1c by a mean of 1.6 percentage points vs. 0.4% for placebo at 68 weeks. [13] SURMOUNT-2 found tirzepatide 15 mg reduced HbA1c by 2.1 percentage points vs. 0.5% for placebo in a similar population. [10]

Phentermine has no meaningful effect on HbA1c. Stimulant-class sympathomimetics can actually impair insulin sensitivity at higher doses through cortisol and catecholamine release, though this effect is modest at phentermine's therapeutic doses.

For a patient managing both obesity and type 2 diabetes, the choice between a GLP-1 agent and phentermine is not a close call by any metabolic metric.